ClinicaliQ Trial Snapshot
- A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration — Active Not Recruiting • Phase IV • NCT06795048.
- Faricimab injections given every 24 weeks or less maintain vision in treatment-naive wet age-related macular degeneration over 100 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye. Conditions: Neovascular Age-related Macular Degeneration (nAMD) Interventions: Faricimab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 274 participants